Eli Lilly and Company Forecast, price target & analysts
Eli Lilly and Company Target price 2026 - Analyst rating & recommendation
Eli Lilly and Company Classifications & Recommendation
Eli Lilly and Company Price Target
| Target Price | $1,374.45 |
| Price | $1,149.85 |
| Potential |
19.53%
register free of charge
|
| Number of Estimates | 33 |
|
33 Analysts have issued a price target Eli Lilly and Company 2027 .
The average Eli Lilly and Company target price is $1,374.45.
This is
19.53%
register free of charge
$1,680.00
46.11%
register free of charge
$900.13
21.72%
register free of charge
|
|
| A rating was issued by 38 analysts: 30 Analysts recommend Eli Lilly and Company to buy, 7 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Eli Lilly and Company stock has an average upside potential 2027 of
19.53%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 65.18 | 89.43 |
| 44.70% | 37.21% | |
| EBITDA Margin | 48.62% | 49.33% |
| 16.46% | 1.45% | |
| Net Margin | 31.67% | 39.24% |
| 34.69% | 23.92% |
33 Analysts have issued a sales forecast Eli Lilly and Company 2026 . The average Eli Lilly and Company sales estimate is
This results in the following potential growth metrics:
18 Analysts have issued an Eli Lilly and Company EBITDA forecast 2026. The average Eli Lilly and Company EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
32 Eli Lilly and Company Analysts have issued a net profit forecast 2026. The average Eli Lilly and Company net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 22.95 | 37.27 |
| 95.99% | 62.40% | |
| P/E | 30.85 | |
| EV/Sales | 12.62 |
32 Analysts have issued a Eli Lilly and Company forecast for earnings per share. The average Eli Lilly and Company EPS is
This results in the following potential growth metrics and future valuations:
Eli Lilly and Company...
Current Eli Lilly and Company Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JP Morgan |
Locked
➜
Locked
|
Locked | Sep 28 2026 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Sep 22 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Sep 18 2026 |
| HSBC |
Locked
➜
Locked
|
Locked | Sep 10 2026 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
JP Morgan:
Locked
➜
Locked
|
Sep 28 2026 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Sep 22 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Sep 18 2026 |
|
Locked
HSBC:
Locked
➜
Locked
|
Sep 10 2026 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Aug 06 2026 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Aug 06 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
